GlassScriptPhysician profile
Altee S Johnson
NPI 1386869410
$4,318.86
in general payments reported to CMS, 2019-2025
28 companies · $75.95 in 2025
The $75.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $1,574 · 2021: $1,548 · 2024: $124 · 2025: $75.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $795.70 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $563.83 | 2019-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $432.93 | 2019-2021 | |
| Allergan, INC. | $375.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $310.62 | 2019-2021 | |
| Esperion Therapeutics, INC. | $302.75 | 2020-2021 | |
| Abbvie INC. | $270.98 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $154.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $136.28 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.52 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $116.95 | 2019 | |
| Glaxosmithkline, LLC. | $100.46 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.03 | 2019-2021 | |
| Pfizer INC. | $69.04 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $64.65 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $61.25 | 2021 | |
| Abbott Laboratories | $59.81 | 2019-2021 | |
| Eisai INC. | $45.26 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $32.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.96 | 2020 | |
| Currax Pharmaceuticals LLC | $28.54 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $27.58 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $24.79 | 2025 | |
| Daiichi Sankyo INC. | $16.63 | 2021 | |
| Sanofi Pasteur INC. | $15.68 | 2019 | |
| Dexcom, INC. | $13.22 | 2021 | |
| Horizon Therapeutics Plc | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Altee Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.